Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-21-012128

Chief R&D Officer sold 24,141 shares at $22.37 ($540,034)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2021-02-16 Sale −24,141 $22.37 $540,034 266,176 D: show line 1 in the form
Open-market sales · 24,141 sh · avg $22.37 · $540,034
Loading xslF345X03/doc4.xml…